Indoximod
| Code | Size | Price |
|---|
| TAR-T6543-200mg | 200mg | £106.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Indoximod is a methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2, 3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.
CAS:
110117-83-4
Formula:
C12H14N2O2
Molecular Weight:
218.256
Pathway:
Metabolism
Purity:
0.995
SMILES:
Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12
Target:
Indoleamine 2,3-Dioxygenase (IDO)
References
Hou DY, et al. Cancer Res. 2007, 67(2), 792-801.
Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer. Molecular Cancer Research. 2019: molcanres. 0239.2019
Metz R, et al. Oncoimmunology. 2012, 1(9), 1460-1468.
Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer[J]. Molecular Cancer Research. 2020, 18(1): 105-117.
Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer[J]. Molecular Cancer Research. 2019: molcanres. 0239.2019.